{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:38:53Z","timestamp":1785775133900,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["209774"],"award-info":[{"award-number":["209774"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.gastha.2024.08.015","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T22:49:29Z","timestamp":1724453369000},"page":"100536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nucleos(t)ide Analog Treatment Discontinuation in Chronic Hepatitis B Virus Infection: A Systematic Literature Review"],"prefix":"10.1016","volume":"4","author":[{"given":"Robert","family":"Gish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadi","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saifuddin","family":"Kharawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Elston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyeta","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2024.08.015_bib1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib2","series-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact 2021","year":"2021"},{"key":"10.1016\/j.gastha.2024.08.015_bib3","series-title":"Health-related quality of life and stigma related to chronic hepatitis B: a systematic literature review the International Liver Congress 2021 (European Association for the Study of the Liver)","year":"2020"},{"key":"10.1016\/j.gastha.2024.08.015_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastha.2024.08.015_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13643-019-1126-1","article-title":"Antiviral treatment for treatment-na\u00efve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials","volume":"8","author":"Wong","year":"2019","journal-title":"Syst Rev"},{"key":"10.1016\/j.gastha.2024.08.015_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2468-1253(23)00455-7","article-title":"Urgent need for lived experience in hepatitis B guideline development","volume":"9","author":"Freeland","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","article-title":"Functional cure for chronic hepatitis B: accessibility, durability, and prognosis","volume":"18","author":"Song","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.gastha.2024.08.015_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.08.015_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3350\/cmh.2022.0420","article-title":"Safety Considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: first, do No Harm","volume":"29","author":"Hsu","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib13","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.12998\/wjcc.v9.i24.6979","article-title":"Discontinuation of antiviral therapy in chronic hepatitis B patients","volume":"9","author":"Medas","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.gastha.2024.08.015_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastha.2024.08.015_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2011.04738.x","article-title":"Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy","volume":"34","author":"Liang","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2024.08.015_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cgh.2014.10.023","article-title":"Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation","volume":"13","author":"Chang","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib17","first-page":"4883","article-title":"Cessation of nucleos(t)ide analogue therapy in non-cirrhotic hepatitis B patients with prior severe acute exacerbation","volume":"10","author":"Lai","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.gastha.2024.08.015_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JCMA.0000000000000247","article-title":"Nucleos(t)ide analogue continuous therapy associated with reduced adverse outcomes of chronic hepatitis B","volume":"83","author":"Su","year":"2020","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.gastha.2024.08.015_bib20","first-page":"484A","article-title":"High FIB-4 index predicts liver decompensation after discontinuation of antiviral therapy in patients of chronic hepatitis B","volume":"74","author":"Su","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib21","article-title":"IDDF2018-ABS-0154 Virological and clinical outcomes after cessation of nucleos(t)ide analogue therapy for chronic hepatitis b \u2013 a prospective cohort study in central Taiwan","volume":"67","author":"Yen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2024.08.015_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jmv.20465","article-title":"Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients","volume":"77","author":"Jang","year":"2005","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.gastha.2024.08.015_bib23","first-page":"476A","article-title":"Distinct different relapse patterns but similar HBeAg sero-reversion rate after cessation of entecavir and tenofovir in HBeAg-positive chronic hepatitis B patients","volume":"74","author":"Peng","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2024.08.015_bib25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of Nucles(t)ide analogue therapy","volume":"18","author":"Fan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib26","article-title":"Serum pregenomic RNA combined with hepatitis B core-related antigen helps predict the risk of virological relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.gastha.2024.08.015_bib27","first-page":"S1","article-title":"Serum levels of pgRNA and HBcrAg are associated with viral relapse after cessation of nucleotide analogues therapy in chronic hepatitis B patients","volume":"16","author":"Chen","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastha.2024.08.015_bib28","article-title":"Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B (CHBE-) patients who discontinued effective entecavir (ETV) or tenofovir (TDF) therapy in the prospective DARING-B Greek study","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib29","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2024.08.015_bib30","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/S0168-8278(22)00925-4","article-title":"HBeAg-positive patients with HBsAg < 135IU\/ml or HBcrAg <3.6logU\/ml have more chance to be HBsAg loss after nucleos(t)ide analogue cessation","volume":"77","author":"Xie","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib31","article-title":"End of treatment HBsAg, HBcrAg and HBV RNA levels predict risk of off-treatment ALT flares in patients with chronic hepatitis B","volume":"72","author":"Brakenhoff","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)01979-1","article-title":"Serum HBV RNA levels are associated with risk of hepatitis flare after stopping NA therapy in HBeAg-negative patients","volume":"77","author":"Jackson","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.08.015_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2893.2005.00606.x","article-title":"Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B","volume":"12","author":"Shin","year":"2005","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2024.08.015_bib35","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.14309\/ajg.0000000000002176","article-title":"Withdrawal of long-term nucleotide analog therapy in chronic hepatitis B: outcomes from the withdrawal phase of the HBRN immune active treatment trial","volume":"18","author":"Feld","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2024.08.015_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/v11080687","article-title":"Caucasian ethnicity, but not treatment cessation is associated with HBsAg loss following nucleos(t)ide analogue-induced HBeAg seroconversion","volume":"11","author":"Van Hees","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.gastha.2024.08.015_bib37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1665-2681(19)31020-8","article-title":"Hepatitis B viral load and risk of HBV-related liver disease: from East to West?","volume":"11","author":"Harkisoen","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/341508","article-title":"Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins","volume":"186","author":"Marx","year":"2002","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.gastha.2024.08.015_bib39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fimmu.2014.00441","article-title":"Age-dependent immune events during HBV infection from birth to adulthood: an Alternative interpretation","volume":"5","author":"Bertoletti","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.gastha.2024.08.015_bib40","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after Nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib41","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: a systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastha.2024.08.015_bib42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/cid\/ciad506","article-title":"Chronic hepatitis B finite treatment: similar and different concerns with new drug classes","volume":"78","author":"Peters","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastha.2024.08.015_bib43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A\u00a0multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van B\u00f6mmel","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2024.08.015_bib45","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference","volume":"79","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2024.08.015_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12072-022-10441-5","article-title":"Hepatitis B: \"treat all\" or \"treat select\"","volume":"17","author":"Jindal","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastha.2024.08.015_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A\u00a0case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV 'cure'","volume":"77","author":"Agarwal","year":"2022","journal-title":"J\u00a0Hepatol"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:14:54Z","timestamp":1737429294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572324001304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2772572324001304"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2024.08.015","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleos(t)ide Analog Treatment Discontinuation in Chronic Hepatitis B Virus Infection: A Systematic Literature Review","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2024.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100536"}}